Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination-Reference-Cited by-同舟云学术

Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

Published:2022-04 Issue:4 Volume:3 Page:100603
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Mantus Grace,Nyhoff Lindsay E.,Edara Venkata-Viswanadh,Zarnitsyna Veronika I.,Ciric Caroline R.,Flowers Maria W.,Norwood Carson,Ellis Madison,Hussaini Laila,Manning Kelly E.,Stephens Kathy,Anderson Evan J.,Ahmed Rafi,Suthar Mehul S.,Wrammert Jens

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference40 articles.

1. An interactive web-based dashboard to track COVID-19 in real time;Dong;Lancet Infect. Dis.,2020

2. The spike protein of SARS-CoV--a target for vaccine and therapeutic development;Du;Nat. Rev. Microbiol.,2009

3. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients;Kreer;Cell,2020

4. Evaluation of cellular and serological responses to acute SARS-CoV-2 infection demonstrates the functional importance of the receptor-binding domain;Mantus;J. Immunol.,2021

5. Human-IgG-neutralizing monoclonal antibodies block the SARS-CoV-2 infection;Wan;Cell Rep.,2020

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 mRNA vaccination responses in individuals with sickle cell disease: an ASH RC Sickle Cell Research Network Study;Blood Advances;2024-08-29

2. Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers;BMC Infectious Diseases;2024-08-01

3. Durability of immune responses to SARS-CoV-2 infection and vaccination;Seminars in Immunology;2024-05

4. Immunogenicity Assessment of the SARS-CoV-2 Protein Subunit Recombinant Vaccine (CoV2-IB 0322) in a Substudy of a Phase 3 Trial in Indonesia;Vaccines;2024-04-01

5. Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection;Vaccines;2024-02-10